Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

DanDrit Biotech USA, Inc. Common Stock (OB:DDRT)

Business Focus: N/A

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEC Form 4 filings for DDRT*US within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Feb 26, 2018 10:11 ET
Dandrit Biotech Announces Filing Of Listing Application To The Nasdaq Capital Market
LOS ANGELES, Feb. 26, 2018 /PRNewswire/ -- DanDrit Biotech USA, Inc. ("DanDrit") finalized its acquisition (the "Acquisition") of Enochian Biopharma Inc. ("Enochian") on February 16, 2018. Enochian develops innovative proprietary technologies in HIV/AIDS. DanDrit believes that through the acquisition, Enochian's technologies will enhance DanDrit's research and development efforts and add to its pipeline.
Read full article
Feb 19, 2018 17:48 ET
DanDrit Biotech Announces Completion Of The Acquisition Of Enochian
LOS ANGELES, Feb. 19, 2018 /PRNewswire/ -- DanDrit Biotech USA, Inc. ("DanDrit") is pleased to announce the completion of its previously reported acquisition (the "Acquisition") of Enochian Biopharma Inc. ("Enochian") on February 16, 2018. As a result of the Acquisition, DanDrit owns a perpetual, fully paid up, royalty free, sublicensable, exclusive, license to new technology platforms for the treatment of HIV, including combinatory gene therapy methods, and Enochian is now a wholly owned subsidiary of DanDrit.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
--
--
--
Price to Sales - TTM
--
--
--
Price to Book - most recent quarter
--
--
--
Price to Cash Flow per share - TTM
--
--
--
Price to Free Cash Flow per share - TTM
--
--
--
See all valuations

Business Summary

Sector:  N/A Industry:  N/A

See business summary

 

Twitter

Search (past week) for $DDRT

  • No tweets found